Quantum BioPharma Ltd. announces an At-the-Market offering agreement with H.C. Wainwright & Co., LLC, allowing the sale of Class B Shares up to US$21,225,000. Sales will be made through Nasdaq at prevailing market prices, with proceeds intended for clinical studies and general purposes. The offering is being conducted in the U.S. under a registration statement filed with the SEC. Quantum focuses on developing drug candidates for neurodegenerative and metabolic disorders, including Lucid-MS for multiple sclerosis and UNBUZZD™ for alcohol misuse. Forward-looking statements caution of risks and uncertainties in drug development and market conditions.

Read more at GlobeNewswire: Quantum BioPharma Ltd. Provides Corporate Update